GeneralBreaking NewsBreakingLatest News
Cancer Drug Markups Hit 700% Despite 2019 Cap; Will Government Succeed This Time?
Sentiment: NeutralHigh Priority
What Happened?
Seven years after the government intervened to limit cancer drug markups, a new effort is underway following a Supreme Court directive. The latest analysis reveals significant price reductions, but questions remain about the effectiveness of past measures.
Key points
- The National Pharmaceutical Pricing Authority (NPPA) announced a second round of trade margin rationalisation covering 137 anti-cancer drugs.
- The average price cut across the revised list is about 38%, with some drugs seeing reductions over 70%.
- Despite the 2019 intervention, many cancer drug prices have increased, with some markups exceeding 700%.
- The government relies on pharmaceutical companies for pricing data, complicating independent verification.
- High-cost medicines from multinational companies have seen little to no price reduction.
Key insights
- The government's one-time interventions may not effectively control rising drug prices in the long term.
- Without continuous monitoring, excessive margins could return, impacting patient affordability.
- The disparity in price reductions between local and multinational companies raises concerns about equitable access to cancer treatments.
Why it matters
The rising cost of cancer treatment affects patient access to necessary medications.
Source
India Today
